Advertisement

Effect of rhEPO on survival in anaemic cancer patients receiving chemotherapy

  • T. J. Littlewood

Abstract

Anaemia is common in patients with malignant disease and most commonly will be attributed to the anaemia of chronic diseases1 and to the myelosuppressive effects of treatment with chemotherapy and/or radiotherapy.

Keywords

Chronic Lymphocytic Leukemia Recombinant Human Erythropoietin Murine Fibrosarcoma Cancer Related Anaemia Anaemic Cancer Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Spivak JL (1994) Recombinant human erythropoietin and the anemia of cancer. Blood 84: 997–1004PubMedGoogle Scholar
  2. 2.
    Miller CB, Jones RJ, Piantadosi S et al (1990) Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322 (24): 1689–1692PubMedCrossRefGoogle Scholar
  3. 3.
    San Miguel JF, Garcia-Sanz R, Gonzalez M et al (1995) A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 85 (2): 448–455PubMedGoogle Scholar
  4. 4.
    Coiffier B (1999) Anemia associated with non-platinum chemotherapy for Hodgkin’s lymphoma or non-Hodgkin’s lymphoma. Eur J Cancer 35: Suppl 4, S331 (Abstr 1331)Google Scholar
  5. 5.
    Barrett-Lee PJ, Bailey NP, O’Brien MER, Wager E (2000) Large scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 82: 93–97PubMedCrossRefGoogle Scholar
  6. 6.
    Thomas ML (1998) Impact of anemia and fatigue on quality of life in cancer patients: a brief review. Med Oncol 15: Suppl 1, S3 - S7Google Scholar
  7. 7.
    Manegold C (1998) The causes and prognostic significance of low haemoglobin levels in tumor patients Strahlenther Onkol 174: Suppl IV, 17–19Google Scholar
  8. 8.
    Durie BGM, Salmon SE (1975) Cancer 36: 842–854PubMedCrossRefGoogle Scholar
  9. 9.
    Binet JL, Auquier A, Dighiero G et al (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis Cancer 48: 198–206Google Scholar
  10. 10.
    Albain KS, Crowley JJ, LeBlanc M et al (1991) Survival determinants in extensive stage non small cell lung cancer. J Clin Oncol 9: 1618–1626PubMedGoogle Scholar
  11. 11.
    Ohlhauser C, Bülzebruck H, Ebert W et al (1997) Prognostic factors for survival in inoperable non-small-cell lung cancer. A multivariate regression analysis of 456 patients with radiation therapy. Onkologie 20: 126–131CrossRefGoogle Scholar
  12. 12.
    Molls M, Stadler P, Becker A, Feldmann HJ, Dunst J (1998) Relevance of oxygen in radiation oncology. Strahlenther Onkol 174: Suppl IV, 13–16Google Scholar
  13. 13.
    Kelleher DK, Matthiensen U, Thews O, Vaupel P (1996) Blood flow, oxygenation and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res 56: 4728–4734PubMedGoogle Scholar
  14. 14.
    Hockel M, Schlenger K, Arral B, Mitze M, Schäffer U, Vaupel P (1996) Association between tumour hypoxia and malignant progression in advanced carcinoma of the uterine cervix. Cancer Res 56: 4509–4515PubMedGoogle Scholar
  15. 15.
    Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhurst MW (1997) Tumour hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38: 285–289PubMedCrossRefGoogle Scholar
  16. 16.
    Höckel M, Schlenger K, Höckel S, Vaupel P (1999) Association between tumor hypoxia and malignant progression: the clinical evidence in cancer of the uterine cervix. In: Tumor Hypoxia. Vaupel P, Kelleher DK (eds) Wissenschaftliche Verlagsgesellschaftmbh, Stuttgart, 65–74Google Scholar
  17. 17.
    Hall EJ (1994) The oxygen effect and reoxygenation. In: Hall EJ (ed) Radio-biology for the radiologist, 4`h edition. Philadelphia, Lippincott, 133–152Google Scholar
  18. 18.
    Frommhold H, Guttenberger R, Hence M (1998) The impact of blood haemoglobin content on the outcome of radiotherapy. The Freiburg experience. Strahlenther Onkol 174: Suppl 4, 31–34Google Scholar
  19. 19.
    Thomas G (2001) The effect of hemoglobin level on radiotherapy outcomes: the Canadian experience. Semin Oncol 28: Suppl 8, 60–65Google Scholar
  20. 20.
    Grogan M (1999) The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86: 1528–1536PubMedCrossRefGoogle Scholar
  21. 21.
    Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumours: a review. Cancer Res 49: 6449–6465PubMedGoogle Scholar
  22. 22.
    Pirollo KF, Bouber KB, Chang EH (2000) Does p53 status influence tumour response to anticancer therapies? Anticancer Drugs 11: 419–432PubMedCrossRefGoogle Scholar
  23. 23.
    Teicher BA, Holden SA, Al-Achi A, Herman TS (1990) Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 50: 3339–3344PubMedGoogle Scholar
  24. 24.
    Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91: 1616–1634PubMedCrossRefGoogle Scholar
  25. 25.
    Demetri GD, Kris M, Wade J et al (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 16: 3412–3425PubMedGoogle Scholar
  26. 26.
    Glaspy J, Bukowski R, Steinberg D et al (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15: 1218–1234PubMedGoogle Scholar
  27. 27.
    Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865–2874PubMedGoogle Scholar
  28. 28.
    Glaser C, Millesi W, Kornek G et al (2001) Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50: 705–715PubMedCrossRefGoogle Scholar
  29. 29.
    Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N (2001) Erythropoietin induces tumor regression and antitumor responses in murine myeloma models. Proc Natl Acad Sci USA 98: 5181–5186PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2002

Authors and Affiliations

  1. 1.Department of HaematologyJohn Radcliffe HospitalOxfordUK

Personalised recommendations